The Effects of Hydrocortisone on Systemic Arterial Blood Pressure and Urinary Protein Excretion in Dogs
Overview
Veterinary Medicine
Affiliations
Background: Hypertension and proteinuria are commonly recognized in dogs with spontaneous hypercortisolism. There is, however, little information regarding the effect of exogenous glucocorticoids on blood pressure (BP) and proteinuria and whether these changes are reversible.
Hypothesis: Hydrocortisone administration increases systemic BP and urinary protein excretion, and these effects are reversible after hydrocortisone withdrawal.
Animals: Six control dogs and 6 dogs treated with hydrocortisone.
Methods: BP, urine protein : creatinine ratio (UPC), microalbuminuria (MALB), urine albumin : creatinine ratio (UAC), and urine gel electrophoresis were evaluated before, during, and after administration of hydrocortisone (8 mg/kg PO q12h for 12 weeks) or placebo.
Results: BP and UPC increased substantially during hydrocortisone administration from 123 mmHg (range 114-136 mmHg) and 0.17 (0.15-0.28) to a maximum of 143 mmHg (128-148 mmHg) and 0.38 (0.18-1.78), respectively, on day 28. MALB developed in 4 dogs and UAC significantly increased in all dogs during hydrocortisone administration with the maximum on day 84. Both increases in BP and proteinuria were reversible and completely resolved within 1 month after stopping hydrocortisone administration. SDS-AGE revealed the proteinuria to be primarily albuminuria with a pronounced increase during hydrocortisone treatment. Furthermore, a protein of 25-30 kDa was found in male dogs, identified by mass spectrometry to be arginine esterase, the major secretory prostatic protein.
Conclusions And Clinical Importance: Long-term hydrocortisone treatment results in significant but only mild increases in systemic BP and urinary protein excretion, which are both reversible within 1 month after discontinuation of hydrocortisone.
Establishment of a reference interval for urinary albumin-to-creatinine ratio in dogs.
Falus F, Vizi Z, Szabo K, Muller L, Reiczigel J, Balogh N Vet Clin Pathol. 2022; 51(4):585-590.
PMID: 35791959 PMC: 10084387. DOI: 10.1111/vcp.13149.
Barker L, McManus S, Adamantos S, Black V J Small Anim Pract. 2022; 63(8):619-623.
PMID: 35508589 PMC: 9542946. DOI: 10.1111/jsap.13503.
Navarro P, Gil L, Martin G, Fernandez-Barredo S J Vet Diagn Invest. 2021; 33(4):632-639.
PMID: 34088253 PMC: 8229835. DOI: 10.1177/10406387211020117.
Light chain myeloma and detection of free light chains in serum and urine of dogs and cats.
Harris R, Miller M, Donaghy D, Ashton L, Langston C, Shockey T J Vet Intern Med. 2021; 35(2):1031-1040.
PMID: 33634914 PMC: 7995444. DOI: 10.1111/jvim.16070.
Side Effects to Systemic Glucocorticoid Therapy in Dogs Under Primary Veterinary Care in the UK.
Elkholly D, Brodbelt D, Church D, Pelligand L, Mwacalimba K, Wright A Front Vet Sci. 2020; 7:515.
PMID: 32923470 PMC: 7457010. DOI: 10.3389/fvets.2020.00515.